China Issues Deepening Health Care Reform Plan To Reign In Drug Prices
This article was originally published in PharmAsia News
Prices for pharmaceuticals widely used in clinics could be the target of efforts by the Chinese government to curb costs. At the same time, an aggressive move to stamp out kickbacks for drug sales is under way as China’s federal cabinet, or State Council, moves to deepen health care reforms.
You may also be interested in...
China insurance giant snatches up stakes in Japanese pharma and a traditional Chinese medicines maker with a $465m spending spree.
With vaccines perhaps the ultimate weapon to fight the coronavirus, a developer in China sees a big chunk of investment with potentially more companies to see funding coming.
Which drug candidates represent hope, and which hype? The Scrip team examine the COVID-19 pipeline, lessons from China, and some long term impacts on the sector.